Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Up 525.9% in May

Sunshine Biopharma, Inc. (NASDAQ:SBFMGet Rating) saw a large increase in short interest in the month of May. As of May 15th, there was short interest totalling 1,660,000 shares, an increase of 525.9% from the April 30th total of 265,200 shares. Approximately 9.2% of the company’s shares are short sold. Based on an average daily volume of 1,290,000 shares, the days-to-cover ratio is currently 1.3 days.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Jane Street Group LLC bought a new position in Sunshine Biopharma during the 1st quarter worth about $31,000. Virtu Financial LLC acquired a new stake in Sunshine Biopharma during the first quarter worth approximately $34,000. Bank of Montreal Can acquired a new stake in shares of Sunshine Biopharma in the second quarter valued at approximately $40,000. Finally, Two Sigma Investments LP acquired a new stake in shares of Sunshine Biopharma in the third quarter valued at approximately $29,000. Institutional investors and hedge funds own 18.29% of the company’s stock.

Sunshine Biopharma Stock Performance

Shares of SBFM stock traded up $0.00 during trading hours on Friday, reaching $0.59. The company had a trading volume of 141,643 shares, compared to its average volume of 939,707. The company has a 50 day moving average of $0.67 and a 200 day moving average of $0.79. Sunshine Biopharma has a 1-year low of $0.45 and a 1-year high of $1.85.

About Sunshine Biopharma

(Get Rating)

Sunshine Biopharma, Inc is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm’s product include treatment for Coronavirus infections and anticancer drugs.

Further Reading

Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with's FREE daily email newsletter.